Literature DB >> 6143743

Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.

D A Johnson.   

Abstract

The advantages of both long-acting injections and oral administration of neuroleptic agents in treating schizophrenia are discussed. Problems related to patient noncompliance and other factors relevant in evaluating long-term maintenance therapy are considered, as well as variables that influence the duration of maintenance therapy. The results of discontinuation, whether initiated by patient or physician, are discussed, along with the limitations of long-term medication therapy (e.g., depression, dyskinesia, extrapyramidal symptoms). General guidelines are provided for evaluating dose requirements in maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143743

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

Review 1.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 2.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

Authors:  Emmamuel O Akala; Pornruedee Wiriyacoonkasem; Gaofeng Pan
Journal:  Drug Dev Ind Pharm       Date:  2011-03-30       Impact factor: 3.225

4.  Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol.

Authors:  S Almond; O O'Donnell
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

5.  Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles.

Authors:  Wusheng Yin; Emmanuel O Akala; Robert E Taylor
Journal:  Int J Pharm       Date:  2002-09-05       Impact factor: 5.875

6.  Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats.

Authors:  Emmanuel O Akala; Hu Wang; Adedayo Adedoyin
Journal:  Neuropsychobiology       Date:  2008-10-03       Impact factor: 2.328

7.  Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Authors:  Matthias Kirschner; Anastasia Theodoridou; Paolo Fusar-Poli; Stefan Kaiser; Matthias Jäger
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

Review 8.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

9.  Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.

Authors:  Gantt P Galloway; Monika Koch; Ryan Cello; David E Smith
Journal:  BMC Psychiatry       Date:  2005-04-01       Impact factor: 3.630

10.  Antipsychotic prescribing of consultant forensic psychiatrists working in different levels of secure care with patients with schizophrenia.

Authors:  Anna Machin; Lucy McCarthy
Journal:  BJPsych Bull       Date:  2017-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.